Workplace Diesel Exhausts and Gasoline Exposure and Risk of Colorectal Cancer in Four Nordic Countries by Madar Talibov, Jorma Sormunen, Elisabete Weiderpass, Kristina Kjaerheim, Jan-Ivar Martinsen, Per Sparen, Laufey Tryggvadottir, Johnni Hansen, Eero Pukkala

Get full text

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study by Anniina Hyväkkä, Okko‐Sakari Kääriäinen, Tapio Utriainen, Eliisa Löyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jääskeläinen, Päivi Auvinen, Heikki Minn, Maria Sundvall

Get full text

739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler

745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123) by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler

711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, João Manuel Santos, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler

1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (f... by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Lyna Haybout, Claudia Kistler, Tatiana V Kudling

749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results by Marco Donia, Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Eva Ellebaek, Brigitte Dreno, Inge Svane, Amir Khammari, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Tine Monberg, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler